Immuno-Oncology | Specialty

Dr. Hammers Discusses Immunotherapy in RCC

March 2nd 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).

FDA Grants Avelumab Priority Review for Metastatic Urothelial Carcinoma

February 28th 2017

The FDA has granted a priority review to a biologics license application for avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Combos Mark Next Step in Melanoma Immunotherapy

February 27th 2017

Evidence continues to build for the long-term efficacy of PD-1-targeting immunotherapies in melanoma, including fresh data indicating when patients can stop taking the drugs and still maintain a response.

Apolo Discusses Immunotherapy Advances in Bladder Cancer

February 25th 2017

Andrea Apolo, MD, discusses positive early trials exploring various regimens of nivolumab (Opdivo), ipilimumab (Yervoy), and avelumab in bladder cancer.

Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma

February 24th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

Dr. Jain on PD-1 Expression in Nivolumab/Ibrutinib Combination in CLL

February 24th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).

Pembrolizumab Long-Term Survival Rate Could Reach 25% in NSCLC

February 24th 2017

Treatment with pembrolizumab could elicit long-term survival rates of 21% to 25% for previously-treated patients with PD-L1–positive non–small cell lung cancer compared with 3% to 4% for docetaxel.

Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers

February 23rd 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

McDermott Discusses Promising PD-L1/VEGF Combo Findings in Frontline mRCC

February 23rd 2017

David McDermott, MD, discusses the results and the significance of the IMmotion 150 trial in metastatic renal cell carcinoma.

Dr. McDermott on IMmotion150 Trial in RCC

February 22nd 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

First SITC Guidelines in RCC Address Continuing Role of Interleukin-2 and Emergence of Nivolumab

February 21st 2017

New guidelines involving the immunotherapies nivolumab (Opdivo) and interleukin-2 inhibitors have been issued by The Society for Immunotherapy of Cancer to help practicing clinicians manage patients with renal cell carcinoma.

Immunotherapy Requires New Strategies for Oncology Practices

February 21st 2017

Immuno-oncology drugs can improve the level of care in many respects, but they bring a host of problems related to implementation that demands a new set of strategies.

Vogelzang Emphasizes Aggressive Biopsies, Novel Therapies in Urothelial Carcinoma

February 21st 2017

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

Cabozantinib Regimens Active Across Multiple Advanced GU Malignancies

February 21st 2017

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

Combination Makes First-Line Case for Metastatic PD-L1+ RCC

February 21st 2017

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

Dr. Seiwert on Ongoing Trials in Head and Neck Cancer

February 20th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

Dr. Smith on Immunotherapy Potential in Multiple Myeloma

February 20th 2017

Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy in the treatment landscape of multiple myeloma.

Expert Highlights Immunotherapy Advances in Myeloma

February 20th 2017

Eric Smith, MD, PhD, discusses recently reported phase II data combining elotuzumab (Empliciti) with lenalidomide (Revlimid) and dexamethasone.

Checkpoint Inhibitors Continue to Offer New Hope in Urothelial Cancer

February 20th 2017

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Ipilimumab Broadens Nivolumab Activity in Urothelial Cancer

February 19th 2017

Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.